Evolving Management Strategies for Treatment-Resistant Depression - Episode 11

Incorporating Esketamine into Practice for Treatment-Resistant Depression

July 15, 2021

Steven P. Levine, MD, Angelos Halaris, MD, PhD, APA, ACNP, CINP, Lisa Harding, MD, Patricia Ares-Romero, MD, FASAM

Custom ViewPoints Video Program

EP. 1: Prevalence of Treatment-Resistant Depression

EP. 2: IV Ketamine for Treatment-Resistant Depression

EP. 3: Current Guidelines for Managing Treatment-Resistant Depression

EP. 4: Intranasal Esketamine for Treatment-Resistant Depression

EP. 5: Esketamine for Treatment-Resistant Depression: Patient Selection Criteria

EP. 6: Monitoring Patients on Esketamine Therapy for Treatment-Resistant Depression

EP. 7: Response to Esketamine Therapy for Treatment-Resistant Depression

EP. 8: REMS Safety Program for Esketamine in Treatment-Resistant Depression

EP. 9: Treatment-Resistant Depression: Administering Esketamine to Patients

EP. 10: Getting Certified to Administer Esketamine for Treatment-Resistant Depression

EP. 11: Incorporating Esketamine into Practice for Treatment-Resistant Depression

EP. 12: Treatment-Resistant Depression: Financial Support for Esketamine Therapy

EP. 13: Frontline Psychotherapy for Depression

EP. 14: Traditional Classes of Antidepressant Therapies

EP. 15: Electroconvulsive Therapy for Depression

EP. 16: Integrated Care and Treatment-Resistant Depression

Requirements that healthcare clinics must satisfy to become a certified treatment center permitted to administer intranasal esketamine to patients with treatment-resistant depression.